Morgan Stanley initiates Enliven Therapeutics stock at overweight
Covered in this story
What has happened since
- Morgan Stanley is up 0.4% since this was published, 4 days ago.
- Enliven Therapeutics Inc is down 9.8% since this was published, 4 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Morgan Stanley’s $70 target on $ELVN is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Morgan Stanley’s track record →Analyst targets on Morgan Stanley
- Morgan Stanley: $216 → $215 by Jul 2027 via GuruFocus
- RBC Capital Markets: $211 → $243 by Jul 2027 · Sector Perform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Morgan Stanley →Dalsna Finance is currently tracking 39 stories mentioning Morgan Stanley, the earliest published 23 Mar 2026.
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.